Regeneron Pharmaceuticals, Inc.: EPS $20.07 vs $16.42 expected; revenue $5.12B vs $4.56B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 20.07 | 16.42 | +22.2% | 11.83 |
| Revenue (USD bn) | 5.12 | 4.56 | +12.1% | 3.75 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Q3 FY2026 | 20.07 | 16.42 | +22.2% | 5.12 | 4.56 | +12.1% |
| Jul 30, 2026 | Q2 FY2026 | 14.29 | 10.16 | +40.6% | 4.29 | 3.82 | +12.4% |
| Apr 29, 2026 | Q1 FY2026 | 9.47 | 8.91 | +6.3% | 3.61 | 3.48 | +3.6% |
| Jan 30, 2026 | Q4 FY2025 | 11.44 | 10.74 | +6.5% | 3.88 | 3.81 | +1.9% |
| Oct 28, 2025 | Q3 FY2025 | 11.83 | 9.65 | +22.6% | 3.75 | 3.59 | +4.5% |
| Aug 1, 2025 | Q2 FY2025 | 12.89 | 8.43 | +52.9% | 3.68 | 3.29 | +11.8% |
| Apr 29, 2025 | Q1 FY2025 | 8.22 | 8.62 | −4.6% | 3.03 | 3.25 | −6.8% |
| Feb 4, 2025 | Q4 FY2024 | 12.07 | 11.21 | +7.7% | 3.79 | 3.74 | +1.3% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
Regeneron Pharmaceuticals, Inc. results: EPS $20.07 vs $16.42 expected; revenue $5.12B vs $4.56B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 22.2%; revenue above the estimate by 12.1%.
Revenue was up 36.3% from $3.75 billion a year earlier (Q3 FY2025). EPS was up 69.7% from $11.83 a year earlier. On its record, EPS topped analysts' estimates in 6 of 7 earlier comparable reports.
What the results mean
Regeneron Pharmaceuticals, Inc. operates across eye disease, immune disorders and oncology, making demand for its treatment portfolio and its ability to turn research into medicines central to interpreting the results. Revenue growth reflects expanding business activity, but the supplied material does not identify each treatment’s contribution.
The portfolio includes EYLEA for eye diseases, Dupixent for atopic dermatitis and asthma, and Libtayo for cutaneous squamous cell carcinoma. This breadth makes treatment adoption and development and manufacturing costs important to understanding profitability, alongside continued work on medicines addressing unmet medical needs.
What to watch on the earnings call: The earnings call merits attention to management’s explanation of demand across eye disease, immune disorders and oncology, and the products contributing to business growth. Discussion of margins, research and development spending, manufacturing costs and progress in developing medicines for unmet medical needs would also be useful.
For the full analysis of Regeneron Pharmaceuticals, Inc. stock — valuation, scores and financial statements — see the stock page linked with this story.